Johnson Financial Group Inc. Lowers Position in Pfizer Inc. $PFE

Johnson Financial Group Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 114,948 shares of the biopharmaceutical company’s stock after selling 23,366 shares during the quarter. Johnson Financial Group Inc.’s holdings in Pfizer were worth $3,228,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vermillion Wealth Management Inc. lifted its holdings in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares during the last quarter. Triad Wealth Partners LLC raised its position in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the period. Eagle Capital Management LLC raised its position in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares during the period. ETF Store Inc. lifted its stake in Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares in the last quarter. Finally, Delta Financial Advisors LLC boosted its position in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after buying an additional 398 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 1.2%

Pfizer stock opened at $24.75 on Tuesday. The firm has a market capitalization of $141.04 billion, a P/E ratio of 18.89 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The stock’s fifty day simple moving average is $25.19 and its 200-day simple moving average is $26.18.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the firm posted $0.92 EPS. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Morgan Stanley lifted their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Citigroup boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Finally, UBS Group reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.50.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer faces expanded international patent lawsuits over its COVID-19 vaccine, with Arbutus Biopharma and Genevant Sciences seeking damages and possible injunctions. That raises legal and operational uncertainty for the company. Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
• Negative Sentiment: Pfizer was noted as falling more than the broader market in the latest session, reinforcing near-term weakness in the stock. Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
• Negative Sentiment: Erste Group Bank lowered earnings estimates for Pfizer, which can signal softer expectations for future profitability. Erste Group Bank Decreases Earnings Estimates for Pfizer
• Neutral Sentiment: Pfizer has been drawing heavy user interest on Zacks, but the coverage is largely a stock-screening/discussion piece rather than a new company-specific catalyst. Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
• Neutral Sentiment: Separate articles highlighted Pfizer as a possible contender in the $100 billion weight-loss market and as a cheap income stock, which supports the bullish long-term narrative but does not change near-term fundamentals on its own. Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.